• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床和医疗保健利用变量可预测成人克罗恩病患者 90 天内的再次住院,以便进行即时护理风险评估。

Clinical and health care utilization variables can predict 90-day hospital re-admission in adults with Crohn's disease for point of care risk evaluation.

机构信息

Department of Medicine, University of Ottawa, Ottawa, ON, Canada.

Department of Medicine, University of Toronto, Toronto, Ontario, ON, Canada.

出版信息

BMC Gastroenterol. 2024 May 17;24(1):172. doi: 10.1186/s12876-024-03226-7.

DOI:10.1186/s12876-024-03226-7
PMID:38760679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11102236/
Abstract

BACKGROUND

Hospital re-admission for persons with Crohn's disease (CD) is a significant contributor to morbidity and healthcare costs. We derived prediction models of risk of 90-day re-hospitalization among persons with CD that could be applied at hospital discharge to target outpatient interventions mitigating this risk.

METHODS

We performed a retrospective study in persons with CD admitted between 2009 and 2016 for an acute CD-related indication. Demographic, clinical, and health services predictor variables were ascertained through chart review and linkage to administrative health databases. We derived and internally validated a multivariable logistic regression model of 90-day CD-related re-hospitalization. We selected the optimal probability cut-point to maximize Youden's index.

RESULTS

There were 524 CD hospitalizations and 57 (10.9%) CD re-hospitalizations within 90 days of discharge. Our final model included hospitalization within the prior year (adjusted odds ratio [aOR] 3.27, 95% confidence interval [CI] 1.76-6.08), gastroenterologist consultation within the prior year (aOR 0.185, 95% CI 0.0950-0.360), intra-abdominal surgery during index hospitalization (aOR 0.216, 95% CI 0.0500-0.934), and new diagnosis of CD during index hospitalization (aOR 0.327, 95% CI 0.0950-1.13). The model demonstrated good discrimination (optimism-corrected c-statistic value 0.726) and excellent calibration (Hosmer-Lemeshow goodness-of-fit p-value 0.990). The optimal model probability cut point allowed for a sensitivity of 71.9% and specificity of 70.9% for identifying 90-day re-hospitalization, at a false positivity rate of 29.1% and false negativity rate of 28.1%.

CONCLUSIONS

Demographic, clinical, and health services variables can help discriminate persons with CD at risk of early re-hospitalization, which could permit targeted post-discharge intervention.

摘要

背景

克罗恩病(CD)患者的住院再入院是发病率和医疗保健成本的重要因素。我们得出了 CD 患者 90 天再入院风险的预测模型,这些模型可以在出院时应用,以针对减轻这种风险的门诊干预措施。

方法

我们对 2009 年至 2016 年间因急性 CD 相关原因住院的 CD 患者进行了回顾性研究。通过病历回顾和与行政健康数据库的链接,确定了人口统计学、临床和卫生服务预测变量。我们推导出并内部验证了一个 90 天 CD 相关再入院的多变量逻辑回归模型。我们选择了最优的概率截断点,以最大化 Youden 指数。

结果

共有 524 例 CD 住院和 57 例(10.9%)CD 患者在出院后 90 天内再住院。我们的最终模型包括前一年的住院治疗(调整后的优势比[aOR]3.27,95%置信区间[CI]1.76-6.08),前一年的胃肠病医生咨询(aOR 0.185,95%CI 0.0950-0.360),指数住院期间的腹腔内手术(aOR 0.216,95%CI 0.0500-0.934)和指数住院期间新诊断的 CD(aOR 0.327,95%CI 0.0950-1.13)。该模型显示出良好的区分度(校正后的乐观 c 统计值为 0.726)和出色的校准度(Hosmer-Lemeshow 拟合优度检验 p 值为 0.990)。最优模型概率截断点可以识别 90 天再入院,其敏感性为 71.9%,特异性为 70.9%,假阳性率为 29.1%,假阴性率为 28.1%。

结论

人口统计学、临床和卫生服务变量可以帮助识别有早期再入院风险的 CD 患者,从而可以进行有针对性的出院后干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2a7/11102236/7e576d9f3e64/12876_2024_3226_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2a7/11102236/7e576d9f3e64/12876_2024_3226_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2a7/11102236/7e576d9f3e64/12876_2024_3226_Fig1_HTML.jpg

相似文献

1
Clinical and health care utilization variables can predict 90-day hospital re-admission in adults with Crohn's disease for point of care risk evaluation.临床和医疗保健利用变量可预测成人克罗恩病患者 90 天内的再次住院,以便进行即时护理风险评估。
BMC Gastroenterol. 2024 May 17;24(1):172. doi: 10.1186/s12876-024-03226-7.
2
Developing a risk prediction model for 30-day unplanned hospitalization in patients receiving outpatient parenteral antimicrobial therapy.开发门诊肠外抗菌治疗患者 30 天内非计划性住院风险预测模型。
Clin Microbiol Infect. 2019 Jul;25(7):905.e1-905.e7. doi: 10.1016/j.cmi.2018.11.009. Epub 2018 Nov 28.
3
A Validated Prognostic Model and Nomogram to Predict Early-Onset Complications Leading to Surgery in Patients With Crohn's Disease.一种验证的预测模型和诺模图,用于预测克罗恩病患者早期并发症导致手术的风险。
Dis Colon Rectum. 2021 Jun 1;64(6):697-705. doi: 10.1097/DCR.0000000000001881.
4
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响:直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
5
Nonattendance to gastroenterologist follow-up after discharge is associated with a thirty-days re-admission in patients with inflammatory bowel disease: a multicenter study.炎症性肠病患者出院后不按时到胃肠病专家处进行随访与 30 天内再入院相关:一项多中心研究。
Minerva Med. 2021 Aug;112(4):467-473. doi: 10.23736/S0026-4806.21.07442-5. Epub 2021 Apr 21.
6
A "Hospital-Day-1" Model to Predict the Risk of Discharge to a Skilled Nursing Facility.一种用于预测患者住院 1 天内转入康复护理机构风险的“住院 1 天”模型。
J Am Med Dir Assoc. 2019 Jun;20(6):689-695.e5. doi: 10.1016/j.jamda.2019.03.035.
7
Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012.2000年至2012年基于前瞻性人群的初始队列中克罗恩病住院情况的患病率及预测因素
World J Gastroenterol. 2015 Jun 21;21(23):7272-80. doi: 10.3748/wjg.v21.i23.7272.
8
Predicting psychiatric readmission: sex-specific models to predict 30-day readmission following acute psychiatric hospitalization.预测精神科再入院:预测急性精神科住院后 30 天再入院的性别特异性模型。
Soc Psychiatry Psychiatr Epidemiol. 2018 Feb;53(2):139-149. doi: 10.1007/s00127-017-1450-5. Epub 2017 Nov 9.
9
Risk factors for 90-day readmission in veterans with inflammatory bowel disease-Does post-discharge follow-up matter?炎症性肠病退伍军人 90 天再入院的风险因素-出院后随访是否重要?
Mil Med Res. 2018 Feb 8;5(1):5. doi: 10.1186/s40779-018-0153-x.
10
Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.瑞士炎症性肠病住院患者年度健康资源利用及成本的系统分析。
Eur J Gastroenterol Hepatol. 2018 Aug;30(8):868-875. doi: 10.1097/MEG.0000000000001160.

本文引用的文献

1
Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis.早期使用抗 TNF 药物治疗可降低克罗恩病患者长期医疗保健利用率,但对溃疡性结肠炎患者无此作用。
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2607-2618.e14. doi: 10.1016/j.cgh.2022.02.021. Epub 2022 Mar 3.
2
Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study.炎症性肠病的再住院率、费用及风险因素:一项为期16年的全国性研究。
Therap Adv Gastroenterol. 2020 May 20;13:1756284820923836. doi: 10.1177/1756284820923836. eCollection 2020.
3
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
生物制剂在短病程与长病程炎症性肠病中的疗效:一项系统评价和随机对照试验的个体患者数据荟萃分析。
Gastroenterology. 2022 Feb;162(2):482-494. doi: 10.1053/j.gastro.2021.10.037. Epub 2021 Oct 29.
4
Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis.生物制剂时代炎症性肠病的直接成本和医疗保健利用的纵向趋势:来自加拿大基于人群的分析结果。
Am J Gastroenterol. 2020 Jan;115(1):128-137. doi: 10.14309/ajg.0000000000000503.
5
Inflammatory bowel disease readmissions are associated with utilization and comorbidity.炎症性肠病再入院与医疗资源利用和合并症有关。
Am J Manag Care. 2019 Oct;25(10):474-481.
6
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响:直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
7
Trends in emergency department visits and hospitalization rates for inflammatory bowel disease in the era of biologics.生物制剂时代炎症性肠病急诊就诊和住院率的趋势。
PLoS One. 2019 Jan 16;14(1):e0210703. doi: 10.1371/journal.pone.0210703. eCollection 2019.
8
Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study.加拿大炎症性肠病患者护理中的城乡差异:一项基于人群的研究。
Clin Epidemiol. 2018 Nov 8;10:1613-1626. doi: 10.2147/CLEP.S178056. eCollection 2018.
9
Risk factors for 90-day readmission in veterans with inflammatory bowel disease-Does post-discharge follow-up matter?炎症性肠病退伍军人 90 天再入院的风险因素-出院后随访是否重要?
Mil Med Res. 2018 Feb 8;5(1):5. doi: 10.1186/s40779-018-0153-x.
10
Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.新发克罗恩病早期联合免疫抑制与常规治疗的长期结局。
J Crohns Colitis. 2018 Apr 27;12(5):517-524. doi: 10.1093/ecco-jcc/jjy014.